Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD

Journal of the American Society of Nephrology

Volumn 25, Issue 1, 2014, Pages 43-54

  Okamura, Daryl M ^a   Bahrami, Nadia M ^a   Ren, Shuyu ^b   Pasichnyk, Katie ^a   Williams, Juliana M ^a   Gangoiti, Jon A ^c   Lopez Guisa, Jesus M ^a   Yamaguchi, Ikuyo ^a   Barshop, Bruce A ^c   Duffield, Jeremy S ^b   Eddy, Allison A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BROXURIDINE; DRINKING WATER; FREE RADICAL; MERCAPTAMINE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SCLEROPROTEIN; SMAD3 PROTEIN; THIOL PROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATTENUATION; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXTRACELLULAR MATRIX; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; MACROPHAGE CULTURE; MALE; MICROENVIRONMENT; MOUSE; MYOFIBROBLAST; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION; OXIDATIVE STRESS; PHAGOCYTOSIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; URETER OBSTRUCTION;

EID: 84891790934     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012090962     Document Type: Article

References (48)

1. Taguchi K, Fujikawa N, Komatsu M, Ishii T, Unno M, Akaike T,MotohashiH,YamamotoM: Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A 109: 13561-13566, 2012
2. ChurchmanAT,Anwar AA, LiFY, SatoH, IshiiT, Mann GE, Siow RC: Transforming growth factor-beta1 elicits Nrf2-mediated antioxidant responses in aortic smooth muscle cells. J Cell Mol Med 13: 2282-2292, 2009
3. YooSK, StarnesTW,DengQ,HuttenlocherA: Lyn is a redox sensor that mediates leukocyte wound attraction in vivo. Nature 480: 109-112, 2011
4. Latchoumycandane C, Marathe GK, Zhang R, McIntyre TM: Oxidatively truncated phospholipids are required agents of tumor necrosis factor a (TNFa)-induced apoptosis. J Biol Chem 287: 17693-17705, 2012
5. Okamura DM, Himmelfarb J: Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr Nephrol 24: 2309-2319, 2009
6. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G: Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119: 524-530, 2009
7. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts WL: Blood enzymes and oxidative stress in chronic kidney disease: A cross sectional study. AnnClin Lab Sci 41: 331-339, 2011
8. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC:Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 17: 311-321, 2012
9. Gahl WA, Balog JZ, Kleta R: Nephropathic cystinosis in adults: Natural history and effects of oral cysteamine therapy. Ann Intern Med 147: 242-250, 2007
10. Greco M, Brugnara M, Zaffanello M, Taranta A, Pastore A, Emma F: Long-term outcome of nephropathic cystinosis: A 20-year single-center experience.PediatrNephrol25:2459-2467,2010
11. Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, Grange G, Bryson EA, GuillermierM,Hirsch E,Hantraye P,Cheetham ME, Néri C, Alberch J, Brouillet E, Saudou F, Humbert S: Cystamine and cysteamine increase brain levels of BDNF in Huntington disease viaHSJ1b and transglutaminase.JClin Invest 116: 1410-1424, 2006
12. Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH, Puri RK: Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrixmetalloproteinases in amouse model of human pancreatic cancer. PLoS ONE 7: e34437, 2012
13. Dohil R, Meyer L, Schmeltzer S, Cabrera BL, Lavine JE, Phillips SA: The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects. J Pediatr 161: 639-645.e1, 2012
14. Dohil R, Schmeltzer S, Cabrera BL, Wang T, Durelle J, Duke KB, Schwimmer JB, Lavine JE: Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33: 1036-1044, 2011
15. Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, Schneider JA: Understanding intestinal cysteamine bitartrate absorption. J Pediatr 148: 764-769, 2006
16. Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, Saint R, Coutts I, Vickers ME, El Nahas AM, Griffin M: Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 18: 3078-3088, 2007
17. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas A: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 99: 2950-2960, 1997
18. JohnsonTS, SkillNJ, ElNahasAM,OldroydSD, Thomas GL, Douthwaite JA, Haylor JL, Griffin M: Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am SocNephrol 10: 2146-2157, 1999
19. Okamura DM, López-Guisa JM, Koelsch K, Collins S, Eddy AA: Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 293: F575-F585, 2007
20. Okamura DM, Pennathur S, Pasichnyk K, López-Guisa JM, Collins S, Febbraio M, Heinecke J, Eddy AA: CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am SocNephrol 20: 495-505, 2009
21. Deschacht M, Horemans T, Martinet W, Bult H, Maes L, Cos P: Comparative EPR study of different macrophage types stimulated for superoxide and nitric oxide production. Free Radic Res 44: 763-772, 2010
22. Kopprasch S, Pietzsch J, Graessler J: Validation of different chemilumigenic substrates for detecting extracellular generation of reactive oxygen species by phagocytes and endothelial cells. Luminescence 18: 268-273, 2003
23. Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, Chiang WC, Shen J, Chen YM, Wu KD, Tsai TJ, Duffield JS, Lin SL: Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 80: 1170-1181, 2011
24. Ignotz RA, Endo T, Massagué J: Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem262: 6443-6446, 1987
25. Yang J, Dai C, Liu Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 163: 621-632, 2003
26. Ren S, Johnson BG, Kida Y, Ip C, Davidson KC, Lin SL, Kobayashi A, Lang RA, Hadjantonakis AK,Moon RT,Duffield JS: LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci U S A 110: 1440-1445, 2013
27. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL: NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 21: 93-102, 2010
28. Tennezé L, Daurat V, Tibi A, Chaumet-Riffaud P, Funck-Brentano C: A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Br J Clin Pharmacol 47: 49-52, 1999
29. Fidler MC, Barshop BA, Gangoiti JA, Deutsch R, Martin M, Schneider JA, Dohil R: Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br J Clin Pharmacol 63: 36-40, 2007
30. Dohil R, Gangoiti JA, Cabrera BL, Fidler M, Schneider JA, Barshop BA: Long-term treatment of cystinosis in children with twice-daily cysteamine. J Pediatr 156: 823-827, 2010
31. Gangoiti JA, Fidler M, Cabrera BL, Schneider JA, Barshop BA,Dohil R: Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: A pilot study. Br J Clin Pharmacol 70: 376-382, 2010
32. Kawada N, Otogawa K: Role of oxidative stress and Kupffer cells in hepatic fibrosis. J Gastroenterol Hepatol 22[Suppl 1]: S85-S86, 2007
33. Kliment CR, Oury TD: Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 49: 707-717, 2010
34. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S, Phinney S, Miller G: Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 64: 978-991, 2003
35. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ: Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials. Lancet 361: 2017-2023, 2003
36. Pergola PE, KrauthM,Huff JW, FergusonDA, Ruiz S, Meyer CJ, Warnock DG: Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 33: 469-476, 2011
37. Pergola PE, Raskin P, Toto RD,Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J,Warnock DG; BEAM Study Investigators: Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336, 2011
38. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel M, Gabbiani G: Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am J Pathol 180: 1340-1355, 2012
39. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97, 2010
40. Lin SL, Kisseleva T, Brenner DA, Duffield JS: Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173: 1617-1627, 2008
41. Schrimpf C, Duffield JS: Mechanisms of fibrosis: The role of the pericyte. CurrOpinNephrol Hypertens 20: 297-305, 2011
42. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ: NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 15: 1077-1081, 2009
43. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, Jansen-Dürr P, Berger P: ROS signaling byNOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol 25: 503-515, 2011
44. Jézégou A, Llinares E, Anne C, Kieffer-Jaquinod S, O'Regan S, Aupetit J, Chabli A, Sagné C, Debacker C, Chadefaux-Vekemans B, JournetA, André B, Gasnier B: Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc NatlAcadSci U S A 109: E3434-E3443, 2012
45. Go YM, Jones DP: Cysteine/cystine redox signaling in cardiovascular disease. Free Radic Biol Med 50: 495-509, 2011
46. Iyer SS, Accardi CJ, Ziegler TR, Blanco RA, Ritzenthaler JD, RojasM, Roman J, Jones DP: Cysteine redox potential determines proinflammatory IL-1beta levels. PLoS ONE 4: e5017, 2009
47. Iyer SS, Jones DP, Brigham KL, Rojas M: Oxidation of plasma cysteine/cystine redox state in endotoxin-induced lung injury. Am J Respir CellMol Biol 40: 90-98, 2009
48. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA: Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67: 2221-2238, 2005